Nuevolution AB (publ) announces its results for the fourth

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Sep 6, 2016 at 2:15 AM

Nuevolution AB (publ) announces its results for the fourth quarter and full year 2015/16

Stockholm, 6 September 2016. Nuevolution AB (publ) announces its report for the fourth quarter and full year 2015/16. The report is available on the company’s home page (www.nuevolution.com). The following is taken from the quarterly report. Fourth quarter and full year summary · During the fourth quarter of 2015/16, additional pre-clinical studies in Nuevolution’s RORγt inverse agonist (inhibitor) program came out with positive results for its lead and backup candidate. Production of the active pharmaceutical ingredient (API) will commence in September 2016 for the first RORγt inverse agonist candidate. · In the Cytokine X program, proof-of-concept was achieved in a disease relevant mouse model. · In vivo studies are ongoing in the BET inhibitor program and in vitro studies are ongoing in the RORγt agonist program with results of these studies expected in the third and fourth quarter 2016, respectively. · The Janssen Biotech collaboration is proceeding according to schedule. We expect initiation of one additional project within the next six months. · Group revenues for the fourth quarter of 2015/16 amounted to SEK 3.1 (5.6) million. Full year 2015/16: SEK 21.3 (29.8) million. · The fourth quarter of 2015/16 is impacted by significant non-recurring and non-cash expenses for the 2015/21 warrant program of SEK 48.5 million and non -recurring reimbursement of VAT of SEK 2.9 million. Hence, both adjusted and reported figures are shown below. · The adjusted operating loss in the fourth quarter of 2015/16 was SEK -31.2 ( -21.8) million. As reported, the operating loss amounted to SEK -76.7 million ( -21.8). Full year 2015/16: Adjusted operating loss of SEK -91.5 (-64.9) million. As reported, the operating loss was SEK -151.9 million (-64.9), including non -recurring expenses of SEK 60.4 million in expenses for the warrant program and IPO costs of SEK 11.9 million. · The adjusted net loss in the fourth quarter of 2015/16 amounted to SEK -29.1 (-20.0) million. As reported, the net loss was SEK -74.7 million (-20.0). Full -year 2015/16: Adjusted net loss of SEK -84.6 (-54.7) million. As reported, the net loss amounted to SEK -145.0 million (-54.7), including the non-recurring expenses for the IPO and warrant program. · Adjusted earnings per share (EPS) in the fourth quarter of 2015/16 was SEK -0.68 (-0.70), and SEK -1.74 (-0.70) as reported. Full year 2015/16: Adjusted EPS of SEK -2.32 (-2.26), and SEK -3.98 (-2.26) as reported, including non -recurring expenses for the IPO and warrant program. · Net cash at June 30, 2016 was SEK 201.3 (44.0) million. Events occurred after June 30, 2016: On July 1, 2016, an extraordinary shareholder’s meeting (EGM) unanimously resolved to amend the terms and conditions of the company’s incentive program, warrant program 2015/2021, in accordance with the major shareholders’ proposal. The warrant program was expensed in the fourth quarter of 2015/16, as majority pre-approval was obtained prior to the EGM. Message of the CEO “We are pleased with the development of our programs and progress in partnership discussions during the fourth quarter of 2015/16. We continue to expect to enter one or two program licensing agreements and one or two risk-sharing collaborations in the next nine months”, CEO Alex Haahr Gouliaev stated. On Tuesday 6 September at 13:00 CEST, the company’s executive management will host a conference call and webcast discussion of the results and provide an update on the pipeline programs and partnering activities. Access to the event can be obtained as follows: LIVE access on Tuesday 6 September at 13:00 CEST Telephone numbers: SE: +46 85 664 2669 DK: +45 8233 3178 UK: +44 20 3008 9808 US: +1 855 7532 235 Webcast will be available at www.nuevolution.com in the Investors section and at www.financialhearings.com REPLAY access Webcast replay will be available at www.nuevolution.com in the Investors section and at www.financialhearings.com For more information, please contact: Alex Haahr Gouliaev, CEO Phone: +45 3913 0902 Email: ahg@nuevolution.com Henrik Damkjær Simonsen, CFO Phone: +45 3913 0947 Email: hs@nuevolution.com Information about Nuevolution AB (publ) Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology. This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Market Act. The information was sent for publication on Tuesday 6 September, 08.00 (CEST). Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden (ticker: NUE.ST). Västra Hamnen Corporate Finance AB acts as Certified Advisor to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ornellaia's 2026 Harvest: Adapting to Nature's Whims

A Year Marked by Weather's Unpredictable Dance Nobody said making wine was a walk in the park, and the folks at Ornellaia know better than most how to roll with whatever nature throws their way. The 2026 harvest story is as much about unlocking the secrets of the soil as it is about navigating the quirks of the weather. Situated in Bolgheri, Italy, this year's vintage...

EMCO's New Automated Facility Could Shake Industry

A Novel Leap in Production Capacity EMCO Industries just put a solid foot on the accelerator with their brand-new, shiny, fully automated plant over in Claremore, Oklahoma. If you're glancing at heavy-duty trailer springs, you can't ignore the fact that this is a multimillion-dollar investment. Heck, this monstrous 30,000-square-foot facility more than doubles what EMCO...

HelloNation Brings 'Edvertising' to NC REALTORS® Event

HelloNation's Bold Step into Real Estate Networking October 8th to the 11th is shaping up to be a pivotal few days in Wilmington, North Carolina. Here’s the scoop: HelloNation, known for its innovative 'edvertising' model, is joining the bustling crowd at the 2026 NC REALTORS® Convention. This isn’t just any get-together—it's the grandest annual jamboree for real...

Duke Energy's Cost-Protection Plan Shields Ratepayers

Shielding Customers From Data Center Costs Let's get right into the thick of it: Duke Energy's latest move is a strategic one, shrouded in industry terms but with a real impact on regular folks' wallets. The company's agreement with heavyweights like Amazon, Google, and Meta aims to protect existing customers in North Carolina from getting hit with the costs of powering...

U. of Phoenix and LACCD Launch 3+1 Degree Pathway

Opening the Floodgates for Ambitious Community College Students When it comes to climbing the educational ladder, not everyone starts at the same rung. That's a fact we've all come to terms with in one way or another. Enter the University of Phoenix and the Los Angeles Community College District with a solution to expand educational access. The 3+1 Program: A Cost-Saving...

Vitamin Angels Drives Global Nutrition Advancements

Navigating the Waters of Global Nutrition Bet you never thought a vitamin program could spearhead the front lines of healthcare, huh? Vitamin Angels are grinding away under the radar, shifting the landscape for maternal and child nutrition. At the heart of it all is their vision to make UNIMMAP multiple micronutrient supplementation (MMS) a staple in the global playbook....

Gong, Agentforce, Avoma Crowned 2026 CI Champions

Diving Deep into Conversation Intelligence There's a lot to unpack when three software titans hog the spotlight, and that's exactly what's happening in the world of conversation intelligence this year. It's like we've hit the jackpot with Gong, Agentforce Sales, and Avoma carving out their turf as the 2026 Champions, according to the venerable Info-Tech Research Group....

C3EL Expands Federal Footprint with Strategic Contracts

Pushing Boundaries in Federal Contracts What a ride C3EL's had in Government Fiscal Year 2026! Let me tell you, they’ve bagged a bunch of contracts that’d make any company’s mouth water. Kicking things off, they snagged a prime cybersecurity contract from the U.S. Air Force. Considering our current cybersecurity landscape, that's like striking gold. But they...

Wally Disrupts Dental Industry with $25M Funding

A New Breath of Fresh Air for Dental Care Dental visits—a tedious, costly affair we've all dreaded. So, when Wally rolls out an overhaul in this stale landscape, it's worth taking notice. With $25 million in their pockets from Series A funding led by Maveron, Wally's swaggering in with a plan to flip the script on dental care across the nation. Redefining the Dental...

OCI N.V. Secures a Win in Court; EGM Proceeds as Planned

OCI Dodges a Bullet in Amsterdam Court Stepping into the courtroom drama, OCI N.V. just took home a win as the Amsterdam Court of Appeal's Enterprise Chamber gave them a clean bill of health, kicking out the inquiry request from VEB and a bunch of other shareholders. The judges weren't convinced there was anything fishy going on, so they tossed the inquiry petition and...